American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3
Objective To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs). Methods A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and...
Gespeichert in:
| Veröffentlicht in: | Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2021-10, Vol.73 (10), p.e60-e75 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e75 |
|---|---|
| container_issue | 10 |
| container_start_page | e60 |
| container_title | Arthritis & rheumatology (Hoboken, N.J.) |
| container_volume | 73 |
| creator | Curtis, Jeffrey R. Johnson, Sindhu R. Anthony, Donald D. Arasaratnam, Reuben J. Baden, Lindsey R. Bass, Anne R. Calabrese, Cassandra Gravallese, Ellen M. Harpaz, Rafael Kroger, Andrew Sadun, Rebecca E. Turner, Amy S. Williams, Eleanor Anderson Mikuls, Ted R. |
| description | Objective
To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).
Methods
A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID‐19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9‐point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings.
Results
Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID‐19 vaccines in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination.
Conclusion
These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID‐19 vaccines and to facilitate implementation of vaccination strategies for RMD patients. |
| doi_str_mv | 10.1002/art.41928 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8426685</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2558094180</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4718-6b88489f8e174a33b1202b9faa746d90967a7c9ca3636cc9605ef317495f77013</originalsourceid><addsrcrecordid>eNp1kU1rVDEUhi-i2NJ24R-QgBtdTJuvmw8XwjDVWqhUSh2XIZM5dyY1k7TJvcrs3Ln1N_pLmjqdooLZ5MB5eHgPb9M8I_iQYEyPbO4POdFUPWp2KaNi1FLcPt7ORJOd5qCUK1yflljg9mmzwzjjohV8t_kxXkH2zkY0SSHAAlDq0MUShpXtU0iLNToZ_NxGB6hLGU3Op6fHv77_JBpNrXM-2t6niHxEH-sEsS_os--XW4N3yMY5-jAUN4RUvkCA3gZ07AvYAuU1mkIudwK23zzpbChwcP_vNZ_evb2cvB-dnZ-cTsZnI8clUSMxU4or3SkgklvGZoRiOtOdtZKLucZaSCuddpYJJpzT9VzoWGV120mJCdtr3my818NsBXNXI2cbzHX2K5vXJllv_t5EvzSL9NUoToVQbRW8vBfkdDNA6c3KFwch2AhpKIa2rcKaE4Ur-uIf9CoNOdbzKiWlbGswWqlXG8rlVEqG7iEMweauYVMbNr8bruzzP9M_kNs-K3C0Ab75AOv_m8z44nKjvAVGzbDG</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2577753172</pqid></control><display><type>article</type><title>American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Curtis, Jeffrey R. ; Johnson, Sindhu R. ; Anthony, Donald D. ; Arasaratnam, Reuben J. ; Baden, Lindsey R. ; Bass, Anne R. ; Calabrese, Cassandra ; Gravallese, Ellen M. ; Harpaz, Rafael ; Kroger, Andrew ; Sadun, Rebecca E. ; Turner, Amy S. ; Williams, Eleanor Anderson ; Mikuls, Ted R.</creator><creatorcontrib>Curtis, Jeffrey R. ; Johnson, Sindhu R. ; Anthony, Donald D. ; Arasaratnam, Reuben J. ; Baden, Lindsey R. ; Bass, Anne R. ; Calabrese, Cassandra ; Gravallese, Ellen M. ; Harpaz, Rafael ; Kroger, Andrew ; Sadun, Rebecca E. ; Turner, Amy S. ; Williams, Eleanor Anderson ; Mikuls, Ted R.</creatorcontrib><description>Objective
To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).
Methods
A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID‐19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9‐point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings.
Results
Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID‐19 vaccines in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination.
Conclusion
These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID‐19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.</description><identifier>ISSN: 2326-5191</identifier><identifier>ISSN: 2326-5205</identifier><identifier>EISSN: 2326-5205</identifier><identifier>DOI: 10.1002/art.41928</identifier><identifier>PMID: 34346564</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - therapeutic use ; Full Length ; Health care ; Humans ; Immunization ; Immunomodulation ; Infectious diseases ; Iterative methods ; Musculoskeletal Diseases ; Online‐Only Special ; Patients ; Physicians ; Public health ; Rheumatic Diseases ; Rheumatology ; Task forces ; United States ; Vaccine efficacy ; Vaccines ; Viral diseases</subject><ispartof>Arthritis & rheumatology (Hoboken, N.J.), 2021-10, Vol.73 (10), p.e60-e75</ispartof><rights>2021, American College of Rheumatology</rights><rights>2021, American College of Rheumatology.</rights><rights>2021 American College of Rheumatology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4718-6b88489f8e174a33b1202b9faa746d90967a7c9ca3636cc9605ef317495f77013</citedby><cites>FETCH-LOGICAL-c4718-6b88489f8e174a33b1202b9faa746d90967a7c9ca3636cc9605ef317495f77013</cites><orcidid>0000-0002-0897-2272 ; 0000-0002-3225-8351 ; 0000-0003-0591-2976 ; 0000-0001-7695-2022 ; 0000-0002-8907-8976</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fart.41928$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fart.41928$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34346564$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Curtis, Jeffrey R.</creatorcontrib><creatorcontrib>Johnson, Sindhu R.</creatorcontrib><creatorcontrib>Anthony, Donald D.</creatorcontrib><creatorcontrib>Arasaratnam, Reuben J.</creatorcontrib><creatorcontrib>Baden, Lindsey R.</creatorcontrib><creatorcontrib>Bass, Anne R.</creatorcontrib><creatorcontrib>Calabrese, Cassandra</creatorcontrib><creatorcontrib>Gravallese, Ellen M.</creatorcontrib><creatorcontrib>Harpaz, Rafael</creatorcontrib><creatorcontrib>Kroger, Andrew</creatorcontrib><creatorcontrib>Sadun, Rebecca E.</creatorcontrib><creatorcontrib>Turner, Amy S.</creatorcontrib><creatorcontrib>Williams, Eleanor Anderson</creatorcontrib><creatorcontrib>Mikuls, Ted R.</creatorcontrib><title>American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3</title><title>Arthritis & rheumatology (Hoboken, N.J.)</title><addtitle>Arthritis Rheumatol</addtitle><description>Objective
To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).
Methods
A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID‐19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9‐point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings.
Results
Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID‐19 vaccines in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination.
Conclusion
These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID‐19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.</description><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - therapeutic use</subject><subject>Full Length</subject><subject>Health care</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunomodulation</subject><subject>Infectious diseases</subject><subject>Iterative methods</subject><subject>Musculoskeletal Diseases</subject><subject>Online‐Only Special</subject><subject>Patients</subject><subject>Physicians</subject><subject>Public health</subject><subject>Rheumatic Diseases</subject><subject>Rheumatology</subject><subject>Task forces</subject><subject>United States</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Viral diseases</subject><issn>2326-5191</issn><issn>2326-5205</issn><issn>2326-5205</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1rVDEUhi-i2NJ24R-QgBtdTJuvmw8XwjDVWqhUSh2XIZM5dyY1k7TJvcrs3Ln1N_pLmjqdooLZ5MB5eHgPb9M8I_iQYEyPbO4POdFUPWp2KaNi1FLcPt7ORJOd5qCUK1yflljg9mmzwzjjohV8t_kxXkH2zkY0SSHAAlDq0MUShpXtU0iLNToZ_NxGB6hLGU3Op6fHv77_JBpNrXM-2t6niHxEH-sEsS_os--XW4N3yMY5-jAUN4RUvkCA3gZ07AvYAuU1mkIudwK23zzpbChwcP_vNZ_evb2cvB-dnZ-cTsZnI8clUSMxU4or3SkgklvGZoRiOtOdtZKLucZaSCuddpYJJpzT9VzoWGV120mJCdtr3my818NsBXNXI2cbzHX2K5vXJllv_t5EvzSL9NUoToVQbRW8vBfkdDNA6c3KFwch2AhpKIa2rcKaE4Ur-uIf9CoNOdbzKiWlbGswWqlXG8rlVEqG7iEMweauYVMbNr8bruzzP9M_kNs-K3C0Ab75AOv_m8z44nKjvAVGzbDG</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Curtis, Jeffrey R.</creator><creator>Johnson, Sindhu R.</creator><creator>Anthony, Donald D.</creator><creator>Arasaratnam, Reuben J.</creator><creator>Baden, Lindsey R.</creator><creator>Bass, Anne R.</creator><creator>Calabrese, Cassandra</creator><creator>Gravallese, Ellen M.</creator><creator>Harpaz, Rafael</creator><creator>Kroger, Andrew</creator><creator>Sadun, Rebecca E.</creator><creator>Turner, Amy S.</creator><creator>Williams, Eleanor Anderson</creator><creator>Mikuls, Ted R.</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0897-2272</orcidid><orcidid>https://orcid.org/0000-0002-3225-8351</orcidid><orcidid>https://orcid.org/0000-0003-0591-2976</orcidid><orcidid>https://orcid.org/0000-0001-7695-2022</orcidid><orcidid>https://orcid.org/0000-0002-8907-8976</orcidid></search><sort><creationdate>202110</creationdate><title>American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3</title><author>Curtis, Jeffrey R. ; Johnson, Sindhu R. ; Anthony, Donald D. ; Arasaratnam, Reuben J. ; Baden, Lindsey R. ; Bass, Anne R. ; Calabrese, Cassandra ; Gravallese, Ellen M. ; Harpaz, Rafael ; Kroger, Andrew ; Sadun, Rebecca E. ; Turner, Amy S. ; Williams, Eleanor Anderson ; Mikuls, Ted R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4718-6b88489f8e174a33b1202b9faa746d90967a7c9ca3636cc9605ef317495f77013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - therapeutic use</topic><topic>Full Length</topic><topic>Health care</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunomodulation</topic><topic>Infectious diseases</topic><topic>Iterative methods</topic><topic>Musculoskeletal Diseases</topic><topic>Online‐Only Special</topic><topic>Patients</topic><topic>Physicians</topic><topic>Public health</topic><topic>Rheumatic Diseases</topic><topic>Rheumatology</topic><topic>Task forces</topic><topic>United States</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Curtis, Jeffrey R.</creatorcontrib><creatorcontrib>Johnson, Sindhu R.</creatorcontrib><creatorcontrib>Anthony, Donald D.</creatorcontrib><creatorcontrib>Arasaratnam, Reuben J.</creatorcontrib><creatorcontrib>Baden, Lindsey R.</creatorcontrib><creatorcontrib>Bass, Anne R.</creatorcontrib><creatorcontrib>Calabrese, Cassandra</creatorcontrib><creatorcontrib>Gravallese, Ellen M.</creatorcontrib><creatorcontrib>Harpaz, Rafael</creatorcontrib><creatorcontrib>Kroger, Andrew</creatorcontrib><creatorcontrib>Sadun, Rebecca E.</creatorcontrib><creatorcontrib>Turner, Amy S.</creatorcontrib><creatorcontrib>Williams, Eleanor Anderson</creatorcontrib><creatorcontrib>Mikuls, Ted R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Curtis, Jeffrey R.</au><au>Johnson, Sindhu R.</au><au>Anthony, Donald D.</au><au>Arasaratnam, Reuben J.</au><au>Baden, Lindsey R.</au><au>Bass, Anne R.</au><au>Calabrese, Cassandra</au><au>Gravallese, Ellen M.</au><au>Harpaz, Rafael</au><au>Kroger, Andrew</au><au>Sadun, Rebecca E.</au><au>Turner, Amy S.</au><au>Williams, Eleanor Anderson</au><au>Mikuls, Ted R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3</atitle><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle><addtitle>Arthritis Rheumatol</addtitle><date>2021-10</date><risdate>2021</risdate><volume>73</volume><issue>10</issue><spage>e60</spage><epage>e75</epage><pages>e60-e75</pages><issn>2326-5191</issn><issn>2326-5205</issn><eissn>2326-5205</eissn><abstract>Objective
To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).
Methods
A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID‐19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9‐point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings.
Results
Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID‐19 vaccines in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination.
Conclusion
These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID‐19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34346564</pmid><doi>10.1002/art.41928</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-0897-2272</orcidid><orcidid>https://orcid.org/0000-0002-3225-8351</orcidid><orcidid>https://orcid.org/0000-0003-0591-2976</orcidid><orcidid>https://orcid.org/0000-0001-7695-2022</orcidid><orcidid>https://orcid.org/0000-0002-8907-8976</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2326-5191 |
| ispartof | Arthritis & rheumatology (Hoboken, N.J.), 2021-10, Vol.73 (10), p.e60-e75 |
| issn | 2326-5191 2326-5205 2326-5205 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8426685 |
| source | MEDLINE; Access via Wiley Online Library; Alma/SFX Local Collection |
| subjects | Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - therapeutic use Full Length Health care Humans Immunization Immunomodulation Infectious diseases Iterative methods Musculoskeletal Diseases Online‐Only Special Patients Physicians Public health Rheumatic Diseases Rheumatology Task forces United States Vaccine efficacy Vaccines Viral diseases |
| title | American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T14%3A11%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=American%20College%20of%20Rheumatology%20Guidance%20for%20COVID%E2%80%9019%20Vaccination%20in%20Patients%20With%20Rheumatic%20and%20Musculoskeletal%20Diseases:%20Version%203&rft.jtitle=Arthritis%20&%20rheumatology%20(Hoboken,%20N.J.)&rft.au=Curtis,%20Jeffrey%20R.&rft.date=2021-10&rft.volume=73&rft.issue=10&rft.spage=e60&rft.epage=e75&rft.pages=e60-e75&rft.issn=2326-5191&rft.eissn=2326-5205&rft_id=info:doi/10.1002/art.41928&rft_dat=%3Cproquest_pubme%3E2558094180%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2577753172&rft_id=info:pmid/34346564&rfr_iscdi=true |